How to buy Pluristem Therapeutics stock | $5.93

Pluristem Therapeutics Inc is a biotechnology business based in the US. Pluristem Therapeutics shares (PSTI) are listed on the NASDAQ and all prices are listed in US Dollars. Pluristem Therapeutics employs 146 staff and has a trailing 12-month revenue of around USD$23,000.

How to buy shares in Pluristem Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Pluristem Therapeutics. Find the stock by name or ticker symbol: PSTI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pluristem Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$5.93, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pluristem Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Pluristem Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pluristem Therapeutics share price

Use our graph to track the performance of PSTI stocks over time.

Pluristem Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-11.

Latest market close	USD$5.93
52-week range	USD$2.82 - USD$13.29
50-day moving average	USD$9.4829
200-day moving average	USD$9.3419
Wall St. target price	USD$9.6
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.863

Buy Pluristem Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Pluristem Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Pluristem Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pluristem Therapeutics price performance over time

Historical closes compared with the close of $5.93 from 2020-12-11

1 week (2021-01-11)	N/A
1 month (2020-12-22)	-12.28%
3 months (2020-10-18)	N/A
6 months (2020-07-18)	N/A

1 year (2020-01-18)	N/A
2 years (2019-01-18)	N/A
3 years (2018-01-18)	N/A
5 years (2016-01-18)	N/A

Pluristem Therapeutics financials

Revenue TTM	USD$23,000
Gross profit TTM	USD$23,000
Return on assets TTM	-44.81%
Return on equity TTM	-91.77%
Profit margin	0%
Book value	$1.911
Market capitalisation	USD$152 million

TTM: trailing 12 months

Shorting Pluristem Therapeutics shares

There are currently 1.2 million Pluristem Therapeutics shares held short by investors – that's known as Pluristem Therapeutics's "short interest". This figure is 1.8% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting Pluristem Therapeutics shares can be evaluated.

Pluristem Therapeutics's "short interest ratio" (SIR)

Pluristem Therapeutics's "short interest ratio" (SIR) is the quantity of Pluristem Therapeutics shares currently shorted divided by the average quantity of Pluristem Therapeutics shares traded daily (recently around 212369.8943662). Pluristem Therapeutics's SIR currently stands at 5.68. In other words for every 100,000 Pluristem Therapeutics shares traded daily on the market, roughly 5680 shares are currently held short.

However Pluristem Therapeutics's short interest can also be evaluated against the total number of Pluristem Therapeutics shares, or, against the total number of tradable Pluristem Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pluristem Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Pluristem Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0601% of the tradable shares (for every 100,000 tradable Pluristem Therapeutics shares, roughly 60 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pluristem Therapeutics.

Find out more about how you can short Pluristem Therapeutics stock.

Pluristem Therapeutics share dividends

We're not expecting Pluristem Therapeutics to pay a dividend over the next 12 months.

Have Pluristem Therapeutics's shares ever split?

Pluristem Therapeutics's shares were split on a 1:10 basis on 25 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pluristem Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pluristem Therapeutics shares which in turn could have impacted Pluristem Therapeutics's share price.

Pluristem Therapeutics share price volatility

Over the last 12 months, Pluristem Therapeutics's shares have ranged in value from as little as $2.82 up to $13.29. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pluristem Therapeutics's is 2.6546. This would suggest that Pluristem Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Pluristem Therapeutics overview

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Frequently asked questions

• What percentage of Pluristem Therapeutics is owned by insiders or institutions?

  Currently 20.665% of Pluristem Therapeutics shares are held by insiders and 11.636% by institutions.

• How many people work for Pluristem Therapeutics?

  Latest data suggests 146 work at Pluristem Therapeutics.

• When does the fiscal year end for Pluristem Therapeutics?

  Pluristem Therapeutics's fiscal year ends in June.

• Where is Pluristem Therapeutics based?

  Pluristem Therapeutics's address is: Building No. 5, Haifa, Israel, 31905

• What is Pluristem Therapeutics's ISIN number?

  Pluristem Therapeutics's international securities identification number is: US72940R3003

• What is Pluristem Therapeutics's CUSIP number?

  Pluristem Therapeutics's Committee on Uniform Securities Identification Procedures number is: 72940P106